Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Rheumatoid Arthritis
Biotech
Cullinan's new data makes clearest case yet for autoimmune TCEs
When it comes to turning T-cell therapies to autoimmune diseases, CAR-Ts lead the way. But another red-hot modality is beginning to show potential.
James Waldron
Jun 6, 2026 5:15am
Gilead scraps lead arthritis drug from $405M MiroBio buyout
May 29, 2026 7:18am
BeOne shelves 5 cancer programs, halts ph. 2 arthritis trial
May 7, 2026 11:15am
AstraZeneca FLAP inhibitor flunks ph. 2 asthma trial
Apr 29, 2026 8:38am
Lilly reneges on remainder of Rigel RIPK1 deal
Apr 22, 2026 3:00pm
Lynk targets the JAK pot with phase 3 rheumatoid arthritis win
Jan 12, 2026 8:45am
